Evidence map›Paper›PMID 37296274›Full record

ArticleLeukemia2023

Targeting miR-126 in Ph+ acute lymphoblastic leukemia.

Junjing Qiao, Dandan Zhao, Le Xuan Truong Nguyen, Fang Chen, Chen Liang, Katrina Estrella, Lucy Y Ghoda, Nora Heisterkamp, Emanuela C Marcucci, Ya-Huei Kuo and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Junjing Qiao *Department of Hematological Malignancies Translational Science, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA.
Dandan Zhao *Department of Hematological Malignancies Translational Science, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA.
Le Xuan Truong Nguyen *Department of Hematological Malignancies Translational Science, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA.
Fang ChenDepartment of Hematological Malignancies Translational Science, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-8871-2752
Chen LiangDepartment of Hematological Malignancies Translational Science, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA.
Katrina EstrellaDepartment of Hematological Malignancies Translational Science, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA.
Lucy Y GhodaDepartment of Hematological Malignancies Translational Science, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-8212-3586
Nora HeisterkampDepartment of Systems Biology, City of Hope Beckman Research Institute, Duarte, CA, USA.
Emanuela C MarcucciGehr Family Center for Leukemia Research, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA.
Ya-Huei KuoDepartment of Hematological Malignancies Translational Science, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-2595-0419
Guido MarcucciDepartment of Hematological Malignancies Translational Science, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA. gmarcucci@coh.org.ORCID http://orcid.org/0000-0002-3983-5908
Bin ZhangDepartment of Hematological Malignancies Translational Science, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA. bzhang@coh.org.ORCID http://orcid.org/0000-0003-4703-7524

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
Targeting MicroRNAs to Eradicate Leukemia Stem CellsR01CA205247 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI KUO, YA-HUEI, MARCUCCI, GUIDO · 2017 to 2025
$4.8M
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AMLR01CA258981 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GUIDO MARCUCCI, BIN ZHANG · 2022 to 2026
$2.7M
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?R01CA248475 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI MARCUCCI, GUIDO, ZHANG, BIN · 2020 to 2024
$2.5M
NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA205247NCI NIH HHS R01 CA248475NCI NIH HHS R01 CA258981
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MicroRNAsPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansMicroRNAsMIRN126 microRNA, human

Identifiers

PMID37296274
PMCPMC10317835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.